Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.16 +9.6%	$1.58	$0.91 ▼ $6.05	$164.92M	2.1	2.58 million shs	2.81 million shs
FMTX Forma Therapeutics	$20.01	$20.00	$4.95 ▼ $20.68	$957.54M	-0.94	847,595 shs	1 shs
PCVX Vaxcyte	$34.33 -0.7%	$32.75	$27.66 ▼ $121.06	$4.43B	1.2	1.45 million shs	1.03 million shs
SRRK Scholar Rock	$32.13 -1.0%	$31.06	$6.76 ▼ $46.98	$3.05B	0.28	1.28 million shs	997,386 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	0.00%	+3.14%	+30.46%	+39.72%	-61.07%
FMTX Forma Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PCVX Vaxcyte	0.00%	-6.57%	+8.51%	-54.06%	-52.62%
SRRK Scholar Rock	0.00%	-5.20%	+6.22%	-6.54%	+243.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	4.2278 of 5 stars	3.1	2.0	0.0	4.2	2.8	2.5	1.3
FMTX Forma Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	3.1827 of 5 stars	4.6	2.0	0.0	0.0	3.5	1.7	0.0
SRRK Scholar Rock	4.2787 of 5 stars	3.6	2.0	0.0	4.4	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.29	Hold	$5.36	148.32% Upside
FMTX Forma Therapeutics	0.00	N/A	N/A	N/A
PCVX Vaxcyte	3.10	Buy	$136.50	297.61% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	32.79% Upside

Current Analyst Ratings Breakdown

Latest PCVX, FMTX, SRRK, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/22/2025	PCVX Vaxcyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
4/8/2025	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00
4/1/2025	PCVX Vaxcyte	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $100.00
4/1/2025	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$157.00 ➝ $137.00
4/1/2025	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$140.00 ➝ $90.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$35.84M	5.05	N/A	N/A	$4.27 per share	0.51
FMTX Forma Therapeutics	$100.56M	9.52	N/A	N/A	$10.51 per share	1.90
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$13.04 per share	N/A
SRRK Scholar Rock	$33.19M	91.91	N/A	N/A	$3.12 per share	10.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$153.22M	-$3.04	N/A	N/A	N/A	-340.96%	-80.13%	-50.99%	8/6/2025 (Estimated)
FMTX Forma Therapeutics	-$172.96M	-$4.00	N/A	N/A	N/A	N/A	-39.68%	-35.33%	N/A
PCVX Vaxcyte	-$402.27M	-$3.99	N/A	N/A	N/A	N/A	-23.53%	-22.20%	8/5/2025 (Estimated)
SRRK Scholar Rock	-$165.79M	-$2.53	N/A	N/A	N/A	N/A	-145.60%	-91.83%	8/6/2025 (Estimated)

Latest PCVX, FMTX, SRRK, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FMTX Forma Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.75	3.75
FMTX Forma Therapeutics	N/A	12.74	12.74
PCVX Vaxcyte	N/A	17.88	17.88
SRRK Scholar Rock	0.63	3.88	3.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
FMTX Forma Therapeutics	87.39%
PCVX Vaxcyte	96.78%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	2.10%
FMTX Forma Therapeutics	5.79%
PCVX Vaxcyte	3.10%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	80.98 million	Optionable
FMTX Forma Therapeutics	166	47.85 million	45.08 million	Not Optionable
PCVX Vaxcyte	160	129.00 million	120.77 million	Optionable
SRRK Scholar Rock	140	94.95 million	75.64 million	Optionable

PCVX, FMTX, SRRK, and EDIT Headlines

Recent News About These Companies

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13 at 4:15 PM | businesswire.com

California State Teachers Retirement System Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

June 7, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Upgraded at Lifesci Capital

June 6, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Trading 5.9% Higher - Here's Why

June 5, 2025 | marketbeat.com

Lifesci Capital Comments on Scholar Rock Q2 Earnings

June 5, 2025 | marketbeat.com

Lifesci Capital Upgrades Scholar Rock (NASDAQ:SRRK) to Strong-Buy

June 4, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 3, 2025 | marketbeat.com

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

June 2, 2025 | uk.finance.yahoo.com

20,188 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Squarepoint Ops LLC

June 2, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Michael Gilman Sells 3,375 Shares

May 31, 2025 | marketbeat.com

Joshua Reed Sells 5,400 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

May 31, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Kristina Burow Sells 5,400 Shares

May 31, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 6,075 Shares

May 31, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $200,610.00 in Stock

May 31, 2025 | marketbeat.com

Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 3,375 Shares of Stock

May 31, 2025 | insidertrades.com

Scholar Rock (NASDAQ:SRRK) Shares Down 6.2% - What's Next?

May 30, 2025 | marketbeat.com

Wellington Management Group LLP Has $74.58 Million Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 30, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.

May 29, 2025 | marketbeat.com

Millennium Management LLC Sells 524,642 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 29, 2025 | marketbeat.com

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025 | businesswire.com

Nuveen Asset Management LLC Buys 122,638 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, FMTX, SRRK, and EDIT Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.16 +0.19 (+9.64%)

Closing price 04:00 PM Eastern

Extended Trading

$2.15 -0.01 (-0.65%)

As of 07:50 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Forma Therapeutics NASDAQ:FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Vaxcyte NASDAQ:PCVX

$34.33 -0.23 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$34.33 0.00 (-0.01%)

As of 04:20 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Scholar Rock NASDAQ:SRRK

$32.13 -0.32 (-0.99%)

Closing price 04:00 PM Eastern

Extended Trading

$32.10 -0.03 (-0.08%)

As of 06:00 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time